Inhibrx Announces Participation in Upcoming Scientific ConferencesPRNewsWire · Oct 13, 2026
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical ContrastDefense World · Oct 5, 2026
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech SetupMarketBeat · Oct 2, 2026
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying ActivityDefense World · Sep 30, 2026
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying ActivityDefense World · Sep 30, 2026
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 SharesDefense World · Sep 25, 2026Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$2.28 | -$2.34 | Miss |
| May 14, 2026 | -$2.37 | -$2.15 | Beat |
| Mar 19, 2026 | -$2.08 | -$2.11 | Miss |
| Nov 14, 2025 | -$2.08 | -$2.28 | Miss |
| Aug 13, 2025 | -$2.92 | -$1.85 | Beat |
| May 14, 2025 | -$2.55 | -$2.80 | Miss |